Acura Pharmaceuticals ( (ACUR) ) has released a notification of late filing.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Acura Pharmaceuticals, Inc. has filed a Form 12b-25, disclosing a delay in submitting its Form 10-Q (Quarter Report) for the quarter ended March 31, 2026. The late filing adds to a long list of missing reports, including multiple Form 10-K (Yearly Report) and Form 10-Q (Quarter Report) filings dating back to 2022.
The company cites severe liquidity constraints as the core reason for the delay, specifically its struggle to meet day-to-day operating obligations. Management explains that operations currently depend on loans from Abuse Deterrent Pharma, LLC, and there is no assurance that such funding will continue or be sufficient over the longer term.
Acura indicates that, under the standard 12b-25 framework, the delayed Form 10-Q (Quarter Report) could be filed within five calendar days of the original due date. However, the company simultaneously warns that it cannot guarantee when, or even if, it will be able to file this or any of the outstanding quarterly and annual reports.
The company reports that no significant change in operating results versus the prior-year period is anticipated for the quarter to be covered by the late Form 10-Q (Quarter Report). Nonetheless, all such comments around funding, future filings and operational stability are inherently forward-looking and subject to substantial uncertainty given the lack of completed audits and reviews.
Acura has halted its public accounting firm’s review of 2022 and 2023 quarterly results and audit of 2022 and 2023 annual results, and has not engaged auditors for 2024, 2025 or 2026. The notification is signed on behalf of the company by Senior Vice President and Chief Financial Officer Robert A. Seiser, signaling ongoing, though uncertain, efforts toward regulatory compliance and financial reporting.
More about Acura Pharmaceuticals
Average Trading Volume: 120
Technical Sentiment Signal: Sell
Current Market Cap: $13.2K
For an in-depth examination of ACUR stock, go to TipRanks’ Overview page.